AR070430A1 - Inhibidores del receptor de quimioquinas cxcr3 - Google Patents

Inhibidores del receptor de quimioquinas cxcr3

Info

Publication number
AR070430A1
AR070430A1 ARP090100561A ARP090100561A AR070430A1 AR 070430 A1 AR070430 A1 AR 070430A1 AR P090100561 A ARP090100561 A AR P090100561A AR P090100561 A ARP090100561 A AR P090100561A AR 070430 A1 AR070430 A1 AR 070430A1
Authority
AR
Argentina
Prior art keywords
lower alkyl
independently
optionally substituted
membered
substituted
Prior art date
Application number
ARP090100561A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR070430A1 publication Critical patent/AR070430A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

El compuesto 3-(amido o sulfamido)-(4-azinil sustituido) benzamida o benzosulfonamida es util como un inhibidor del receptor de quimioquinas CxCR3, y para prevenir o tratar una enfermedad mediada por el receptor de quimioquinas CxCR3 o afeccion relacionada con la misma en un paciente que lo necesite composicion farmacéutica y usos. Reivindicacion 1: Un compuesto 3-(amido o sulfamido)-4-(4-azinil sustituido)benzamida o benzosulfonamida de formula 1 en la que :Q y Q1 son independientemente CO o SO2; Y es CO o SO2 X es halogeno; m es 1, 2 o 3; R1 es alquilo inferior C1-3 (opcionalmente sustituido (aromático o ciclilo inferior)); R2, R4 y R6 son independientemente H o alquilo inferior opcionalmente sustituido; R3 es grupo aromático opcionalmente sustituido; A es CH o N, o A y R5 considerados juntos forman un espiroazaheterociclilo de 4-7 miembros de la siguiente formula (2); n y p son independientemente 0, 1, 2, 3, 4 o 5, siempre que n y p mayor o igual a 2 pero menor o igual a 5; R5 es JGZ, R8R7NQ1-alquilo inferior o azaheterociclilo de 3-7 miembros opcionalmente sustituido; Z es enlace, CO o SO2; G es alquilo inferior, cicloalquilo C3-7 o heterociclilo de 3-7 miembros; y J es grupo aromático, alcoxicarbonilo inferior, alquiltio inferior, alquilsulfinilo inferior, alquilsulfonilo inferior, alcoxi inferior, R8R7N o heterociclilo de 3-7 miembros opcionalmente sustituido (alquilo inferior o halogeno); R7 y R8 son independientemente H o alquilo inferior; R9 y R10 son independientemente H o alquilo inferior; o una de sus sales, solvatos, N-oxidos, derivados cuaternarios o profármacos farmacéuticamente aceptables, o cualquiera de sus combinaciones.
ARP090100561A 2008-02-19 2009-02-18 Inhibidores del receptor de quimioquinas cxcr3 AR070430A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2973808P 2008-02-19 2008-02-19

Publications (1)

Publication Number Publication Date
AR070430A1 true AR070430A1 (es) 2010-04-07

Family

ID=40527535

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100561A AR070430A1 (es) 2008-02-19 2009-02-18 Inhibidores del receptor de quimioquinas cxcr3

Country Status (25)

Country Link
US (1) US8268828B2 (es)
EP (1) EP2262784B1 (es)
JP (1) JP2011512412A (es)
KR (1) KR20100123835A (es)
CN (1) CN102007108A (es)
AR (1) AR070430A1 (es)
AU (1) AU2009215643A1 (es)
BR (1) BRPI0908815A2 (es)
CA (1) CA2715557A1 (es)
CL (1) CL2009000368A1 (es)
CO (1) CO6241113A2 (es)
CR (1) CR11604A (es)
DO (1) DOP2010000254A (es)
EC (1) ECSP10010409A (es)
IL (1) IL207597A0 (es)
MA (1) MA32191B1 (es)
MX (1) MX2010008397A (es)
NI (1) NI201000132A (es)
NZ (1) NZ587380A (es)
PE (1) PE20091576A1 (es)
RU (1) RU2010138577A (es)
SV (1) SV2010003648A (es)
TW (1) TW200948791A (es)
WO (1) WO2009105435A1 (es)
ZA (1) ZA201005314B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
JP5807971B2 (ja) 2009-04-27 2015-11-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Cxcr3受容体アンタゴニスト
WO2011084985A1 (en) * 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
KR101251788B1 (ko) 2010-12-06 2013-04-08 기아자동차주식회사 차량 연비 정보 단말표시 시스템 및 그 방법
JP6162694B2 (ja) 2011-07-18 2017-07-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung ベンズアミド類
EP2601950A1 (en) 2011-12-06 2013-06-12 Sanofi Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists
CN104080784B (zh) * 2012-01-10 2017-07-18 默克专利有限公司 用作卵泡刺激素调节剂的苯甲酰胺衍生物
EA027595B1 (ru) 2012-02-02 2017-08-31 Актелион Фармасьютиклз Лтд. 4-(бензоимидазол-2-ил)тиазольные соединения и родственные азапроизводные
EP2666769A1 (en) 2012-05-23 2013-11-27 Sanofi Substituted B-amino acid derivatives as CXCR3 receptor antagonist
WO2015011099A1 (en) 2013-07-22 2015-01-29 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
CN107072205B (zh) * 2014-09-10 2022-07-15 Epizyme股份有限公司 Smyd抑制剂
UA119805C2 (uk) 2015-01-15 2019-08-12 Ідорсія Фармасьютікалз Лтд Похідні гідроксіалкілпіперазину як модулятори cxcr3-рецептора
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
CN110520127B (zh) 2017-03-26 2023-05-16 武田药品工业株式会社 作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
CN116410159B (zh) * 2023-06-09 2023-08-22 济南国鼎医药科技有限公司 一种恩曲替尼中间体的制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2052541A5 (es) * 1969-06-13 1971-04-09 Takeda Chemical Industries Ltd
US3840556A (en) * 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US6124319A (en) 1997-01-21 2000-09-26 Merck & Co., Inc. 3,3-disubstituted piperidines as modulators of chemokine receptor activity
US6469002B1 (en) 2001-04-19 2002-10-22 Millennium Pharmaceuticals, Inc. Imidazolidine compounds
US6794379B2 (en) 2001-06-06 2004-09-21 Tularik Inc. CXCR3 antagonists
GB0203994D0 (en) 2002-02-20 2002-04-03 Celltech R&D Ltd Chemical compounds
WO2003101970A1 (en) 2002-06-03 2003-12-11 Smithkline Beecham Corporation Imidazolium cxcr3 inhibitors
US6734659B1 (en) 2002-06-13 2004-05-11 Mykrolis Corporation Electronic interface for use with dual electrode capacitance diaphragm gauges
WO2006088921A2 (en) 2005-02-16 2006-08-24 Schering Corporation Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity
EP1856097B1 (en) * 2005-02-16 2012-07-11 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
US7417045B2 (en) * 2005-02-16 2008-08-26 Schering Corporation Heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
WO2007002742A1 (en) * 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
WO2007047202A1 (en) 2005-10-11 2007-04-26 Schering Corporation Substituted heterocyclic compounds with cxcr3 antagonist activity
US20090143413A1 (en) 2005-11-29 2009-06-04 Adams Alan D Thiazole Derivatives as CXCR3 Receptor Modulators
JP2009530383A (ja) 2006-03-21 2009-08-27 シェーリング コーポレイション Cxcr3拮抗活性を有する、新規ヘテロ環ピリジン置換体
CN101516869A (zh) 2006-07-14 2009-08-26 先灵公司 具有cxcr3拮抗剂活性的杂环取代的哌嗪化合物
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3

Also Published As

Publication number Publication date
NZ587380A (en) 2011-09-30
EP2262784A1 (en) 2010-12-22
ZA201005314B (en) 2011-03-30
DOP2010000254A (es) 2010-08-31
SV2010003648A (es) 2011-01-31
TW200948791A (en) 2009-12-01
NI201000132A (es) 2011-03-16
RU2010138577A (ru) 2012-03-27
AU2009215643A1 (en) 2009-08-27
IL207597A0 (en) 2010-12-30
CA2715557A1 (en) 2009-08-27
PE20091576A1 (es) 2009-11-05
ECSP10010409A (es) 2010-09-30
MA32191B1 (fr) 2011-04-01
US20100305088A1 (en) 2010-12-02
MX2010008397A (es) 2010-08-23
CO6241113A2 (es) 2011-01-20
CN102007108A (zh) 2011-04-06
CL2009000368A1 (es) 2009-06-26
CR11604A (es) 2010-10-05
KR20100123835A (ko) 2010-11-25
WO2009105435A1 (en) 2009-08-27
EP2262784B1 (en) 2014-04-16
JP2011512412A (ja) 2011-04-21
US8268828B2 (en) 2012-09-18
BRPI0908815A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
AR070430A1 (es) Inhibidores del receptor de quimioquinas cxcr3
PE20160751A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR049696A1 (es) Derivados de indol
JO3215B1 (ar) حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
EA201400553A1 (ru) Производные 2-(1,2,3-триазол-2-ил)бензамида и 3-(1,2,3-триазол-2-ил)пиколинамида
MX2013005535A (es) Compuesto de 3- (amino-aril) -piridina.
PE20140934A1 (es) Derivados de pirazol
CY1113715T1 (el) Αναλογα πυριδονης και πυριδαζονης ως ρυθμιστες toy gpr119
AR067674A1 (es) Derivados de pirazol utiles para el tratamiento con un antagonista de receptor ccr2
AR065810A1 (es) Derivados de isoindolina 4'-o-sustituidos,composiciones farmaceuticas que los comprenden y usos de los mismos en el tratamiento del cancer y en otros trastornos donde es necesario el control de la angiogenesis o la inhibicion de citoquinas, incluyendo tnf-alfa.
RU2010116821A (ru) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr
RS54608B1 (en) CGRP RECEPTOR ANTAGONITY
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
CR20130145A (es) Moduladores del receptor gpr119 y el tratamieto de trastornos relacionados con este
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion
PE20141167A1 (es) Piridopirazinas sustituidas como inhibidores novedosos de ptk
AR056883A1 (es) Derivados de 7-azaindol-2 carboxamida, un proceso para la preparacion de los mismos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades asociadas con la modulacion de receptores de h3
ATE475645T1 (de) Pyrrolidinderivate als doppelte nk1/nk3- rezeptorenantagonisten
PE20161378A1 (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y transtornos relacionados
RU2016149804A (ru) Производные бензолсульфонамида и их применение в качестве модуляторов орфанного рецептора y, связанного с ретиноевой кислотой
AR076692A1 (es) Piperidinas sustituidas
PE20090115A1 (es) Derivados de indol-2-il-piperazin-1-il-metanona

Legal Events

Date Code Title Description
FA Abandonment or withdrawal